Tyrosine kinase inhibitors for chronic myelogenous leukemia [4]

New England Journal of Medicine

Volumn 357, Issue 15, 2007, Pages 1556-1558

  Defuentes, Gilles ^a   Bladé, Jean Sébastien ^a   Berets, Olivier ^a  

^a PERCY MILITARY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; LEVOTHYROXINE; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

CHRONIC MYELOID LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; HORMONAL THERAPY; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; LETTER; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; NOTE;

HUMANS; HYPOTHYROIDISM; INDOLES; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 35248872525     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc072356     Document Type: Letter

References (5)

1. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357:258-65.
2. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005;78:433-8.
3. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-4.
4. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351-5.
5. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531-4.